NEUROLOGY 2004;63:2104-2110
© 2004 American Academy of Neurology
Pregabalin relieves symptoms of painful diabetic neuropathy
A randomized controlled trial
H. Lesser, MD, PhD,
U. Sharma, PhD,
L. LaMoreaux, MPH and
R. M. Poole, MD, FACP
From the University of Rochester School of Medicine & Dentistry (Dr. Lesser), Rochester, NY; Pfizer Global Research and Development (Drs. Sharma and LaMoreaux), Ann Arbor, MI; and Pfizer Global Research and Development (Dr. Poole), New London, CT.
Address correspondence and reprint requests to Dr. Harold Lesser, 1415 Portland Ave, Suite 480, Rochester, NY 14621; e-mail: Harold.Lesser{at}viahealth.org
Objective: Pregabalin, an alpha2-delta ligand with analgesic, anxiolytic, and anticonvulsant activity, has been evaluated for treatment of neuropathic pain. The authors assessed the efficacy and tolerability of pregabalin (75, 300, 600 mg/day) vs placebo in patients with diabetic peripheral neuropathy (DPN).
Methods: Patients with a 1- to 5-year history of DPN and average weekly pain score of  4 on an 11-point numeric pain-rating scale were enrolled in a 5-week, double-blind, multicenter, placebo-controlled study. Patients (n = 338) were randomized to receive one of three doses of pregabalin or placebo TID. Pregabalin 600 mg/day was titrated over 6 days; lower doses were initiated on day 1.
Results: Patients in the 300- and 600-mg/day pregabalin groups showed improvements in endpoint mean pain score (primary efficacy measure) vs placebo (p = 0.0001). Improvements were also seen in weekly pain score, sleep interference score, patient global impression of change, clinical global impression of change, SF-McGill Pain Questionnaire, and multiple domains of the SF-36 Health Survey. Improvements in pain and sleep were seen as early as week 1 and were sustained throughout the 5 weeks. Responders (patients with 50% reduction in pain compared to baseline) were 46% (300 mg/day), 48% (600 mg/day), and 18% (placebo). Pregabalin was well tolerated with a low discontinuation rate. The most common adverse events were dizziness and somnolence.
Conclusions: In patients with diabetic peripheral neuropathy, pregabalin demonstrated early and sustained improvement in pain and a beneficial effect on sleep, which were confirmed by positive patient global impression. Pregabalin was well tolerated at all doses.
Received December 24, 2003.
Accepted in final form July 26, 2004.
Drs. Sharma, LaMoreaux, and Poole own stock in Pfizer Global Research and Development. Dr. Poole owns stock in excess of $10,000.
Related Article
-
December 14 Highlights
Neurology 2004 63: 1992-1993.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
D. M. Simpson, G. Schifitto, D. B. Clifford, T. K. Murphy, E. Durso-De Cruz, P. Glue, E. Whalen, B. Emir, G. N. Scott, R. Freeman, et al.
Pregabalin for painful HIV neuropathy: A randomized, double-blind, placebo-controlled trial
Neurology,
February 2, 2010;
74(5):
413 - 420.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Davidson, W. Zhang, K. Connor, J. Ji, K. Jobson, Y. Lecrubier, A. McFarlane, D. Newport, D. Nutt, D. Osser, et al.
Review: A psychopharmacological treatment algorithm for generalised anxiety disorder (GAD)
J Psychopharmacol,
January 1, 2010;
24(1):
3 - 26.
[Abstract]
[PDF]
|
|
|
|
|
|
|
D. Nutt, F. Mandel, and F. Baldinetti
Early onset anxiolytic efficacy after a single dose of pregabalin: double-blind, placebo- and active-comparator controlled evaluation using a dental anxiety model
J Psychopharmacol,
November 1, 2009;
23(8):
867 - 873.
[Abstract]
[PDF]
|
|
|
|
|
|
|
F. B. Axelrod and D. Berlin
Pregabalin: A New Approach to Treatment of the Dysautonomic Crisis
Pediatrics,
August 1, 2009;
124(2):
743 - 746.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. B. O'Connor
The Need for Improved Access to FDA Reviews
JAMA,
July 8, 2009;
302(2):
191 - 193.
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. M. Freedman and E. O'Hara
Pregabalin Has Opioid-Sparing Effects Following Augmentation Mammaplasty
Aesthetic Surgery Journal,
July 1, 2008;
28(4):
421 - 424.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Freeman, E. Durso-DeCruz, and B. Emir
Efficacy, Safety, and Tolerability of Pregabalin Treatment for Painful Diabetic Peripheral Neuropathy: Findings from seven randomized, controlled trials across a range of doses
Diabetes Care,
July 1, 2008;
31(7):
1448 - 1454.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M Obermann, M. Yoon, K Sensen, M Maschke, H. Diener, and Z Katsarava
Efficacy of Pregabalin in the Treatment of Trigeminal Neuralgia
Cephalalgia,
February 1, 2008;
28(2):
174 - 181.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. M. Gajraj
Pregabalin: Its Pharmacology and Use in Pain Management
Anesth. Analg.,
December 1, 2007;
105(6):
1805 - 1815.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. L. Blommel and A. L. Blommel
Pregabalin: An antiepileptic agent useful for neuropathic pain
Am. J. Health Syst. Pharm.,
July 15, 2007;
64(14):
1475 - 1482.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. J. Abrams
Pharmacologic Treatments for Pain Associated With Diabetic Peripheral Neuropathies
Journal of Pharmacy Practice,
February 1, 2007;
20(1):
103 - 109.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M. M. Huizinga and A. Peltier
Painful Diabetic Neuropathy: A Management-Centered Review
Clin. Diabetes,
January 1, 2007;
25(1):
6 - 15.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. J. Siddall, M. J. Cousins, A. Otte, T. Griesing, R. Chambers, and T. K. Murphy
Pregabalin in central neuropathic pain associated with spinal cord injury: A placebo-controlled trial
Neurology,
November 28, 2006;
67(10):
1792 - 1800.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. S Jensen, M.-M. Backonja, S. H. Jimenez, S. Tesfaye, P. Valensi, and D. Ziegler
New perspectives on the management of diabetic peripheral neuropathic pain
Diabetes and Vascular Disease Research,
September 1, 2006;
3(2):
108 - 119.
[Abstract]
[PDF]
|
|
|
|
|
|
|
A. Green, S. Owen, P Davies, L Moir, and T. Aziz
Deep Brain Stimulation for Neuropathic Cephalalgia
Cephalalgia,
May 1, 2006;
26(5):
561 - 567.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. E. Argoff, M.-M. Backonja, M. J. Belgrade, G. J. Bennett, M. R. Clark, B. E. Cole, D. A. Fishbain, G. A. Irving, B. H. McCarberg, and M. J. McLean
Consensus Guidelines: Treatment Planning and Options
Mayo Clin. Proc.,
April 1, 2006;
81(4_Suppl):
S12 - S25.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. J. Belgrade, B. E. Cole, B. H. McCarberg, and M. J. McLean
Diabetic Peripheral Neuropathic Pain: Case Studies
Mayo Clin. Proc.,
April 1, 2006;
81(4_Suppl):
S26 - S32.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. J. Rowbotham
Editorial II: Gabapentin: a new drug for postoperative pain?
Br. J. Anaesth.,
February 1, 2006;
96(2):
152 - 155.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. H. Dworkin, J. Katz, and M. J. Gitlin
Placebo response in clinical trials of depression and its implications for research on chronic neuropathic pain
Neurology,
December 29, 2005;
65(12_suppl_4):
S7 - S19.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. J. Rog, T. J. Nurmikko, T. Friede, and C. A. Young
Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis
Neurology,
September 27, 2005;
65(6):
812 - 819.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Rickels, M. H. Pollack, D. E. Feltner, R. B. Lydiard, D. L. Zimbroff, R. J. Bielski, K. Tobias, J. D. Brock, G. L. Zornberg, and A. C. Pande
Pregabalin for Treatment of Generalized Anxiety Disorder: A 4-Week, Multicenter, Double-blind, Placebo-Controlled Trial of Pregabalin and Alprazolam
Arch Gen Psychiatry,
September 1, 2005;
62(9):
1022 - 1030.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Other articles noted
Evid. Based Med.,
August 1, 2005;
10(4):
127 - 128.
[Full Text]
[PDF]
|
|
|
|
